Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Primary Objective: The primary objective of the study is to evaluate the safety of repeat
administration of a dose level of Ad/PNP plus fludarabine phosphate (F-araAMP) which
demonstrated anti-tumor activity in patients with advanced, locoregional head/neck cancer in
a completed phase I study.
Secondary Objective: The secondary objective is to evaluate the antitumor activity of repeat
administration of Ad/PNP plus F-araAMP.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
PNP Therapeutics, Inc.
Collaborators:
Emory University Food and Drug Administration (FDA) Stanford University